Symrise AG
Explore by topic
5-year stock timeline
Apr 2021 — Segment realignment & Sensient fragrance acquisition
Symrise reorganised Flavor and Nutrition into the new "Taste, Nutrition & Health" segment and closed the acquisition of Sensient's Fragrance & Aroma Chemicals business effective 1 Apr 2021 [4]. The market shifted toward viewing the company as a recovery and diversification play. Management positioned M&A alongside organic recovery as the path to scale and margin improvement following COVID disruption [3], [2]. The stock retraced its post-COVID and cyber-incident losses, beginning a re-rating on the back of a clearer growth and strategic profile [2].
Sep 20, 2021 — Admission to the DAX (DAX40)
Symrise was admitted to the German DAX index effective 20 Sept 2021 [23], [24]. The inclusion upgraded the company's index status, drew passive and index-linked investor demand, and raised international visibility—perceived as a large-cap validation of the growth and scale strategy [25]. The stock broke out around the index event with multiple expansion, higher liquidity and trading volumes.
Dec 22, 2021 — Giraffe Foods bolt-on
Symrise completed the acquisition of Giraffe Foods (sauces, dressings, beverages) on 22 Dec 2021 to strengthen Taste & Nutrition offerings [4]. The market saw it as a small, revenue-accretive bolt-on to flesh out the Taste portfolio and reinforce the M&A-led, category diversification message. The stock consolidated as the market digested the acquisition; the overall uptrend remained intact.
Jan 2022 (1–11 Jan) — Portfolio tidy (Velcorin sale) and Schaffelaarbos close
Symrise sold the Velcorin® business to LANXESS effective 1 Jan 2022 and completed the acquisition of Schaffelaarbos (egg-protein specialist) in early January 2022, around 11 Jan 2022 [40], [38]. Market sources cited approximately €160m consideration [44]. The moves signalled strategic capital reallocation—pruning non-core tech while accelerating Pet Nutrition capabilities; investors saw higher-growth exposure being prioritised [38], [40]. The stock re-rated positively on the pet-nutrition angle and tracked an M&A-driven uptrend.
Mar 2022 — FY2021 results and execution confirmation
Symrise published FY2021 and Q4 results showing strong organic growth and recovery from pandemic impacts. Management highlighted durable profitability, proposed a dividend, and noted the prior cyber incident was largely recovered from [2], [3], [5]. The execution validated the "profitable growth" storyline and investor confidence in management's integration and margin control improved. The stock continued its rally on confirmation of recovery and guidance reaffirmation.
Apr–Jul 2022 — Fine-fragrance and APAC pet builds (Romani/Neroli; Wing Pet Food)
Symrise acquired SFA Romani and Groupe Néroli (Grasse) to bolster Fine Fragrance capabilities (announced Apr 2022) and completed the Wing Pet Food transaction during H1 2022 [50], [51], [54], [43]. The moves strategically strengthened high-margin fine-fragrance creative assets and expanded geographic reach in pet nutrition into APAC. The narrative shifted toward platform building across adjacent, higher-growth end markets. The stock showed modest positive momentum on strategic fit, though with limited immediate EPS leverage; it consolidated then gradually moved higher.
End-2022 — Strong FY2022 performance and continued M&A execution
Symrise closed 2022 with continued sales and profit growth while completing multiple targeted acquisitions (Romani/Néroli, Schaffelaarbos, Wing Pet Food, Giraffe Foods) and divestments (Velcorin/colors). Company commentary highlighted resilience to inflation and volatility, with acquisition contributions flowing through [45], [40]. The market increasingly viewed Symrise as a resilient, acquisitive compounder executing a multi-year roll-up and organic growth strategy across Taste, Nutrition & Health and Scent & Care. The stock sustained an uptrend with periodic profit-taking on macro headlines.
Feb 2023 — China JV and biotech positions (pet nutrition vertical)
Symrise formed a JV with Sunner to supply sustainable egg protein into China's pet-food market. Earlier in 2023 it expanded biotech partnerships and holdings to deepen ingredient capabilities [48], [6]. The moves reinforced vertical integration and local market access in the fastest-growing pet market. Investors rewarded clarity on addressable growth in pet nutrition. The stock showed constructive momentum in exposure-linked multiples.
29 Feb – 31 Mar 2024 — CEO succession to Jean-Yves Parisot
The Supervisory Board appointed Dr. Jean-Yves Parisot as CEO (announced 29 Feb 2024; effective 31 Mar 2024) as Dr. Heinz-Jürgen Bertram retired [13], [14]. Management reiterated strategy on Q4 2023 calls [18]. The market treated the change as an orderly, internal succession emphasising continuity over disruption. A short-term relief rally followed the perceived continuity, then the stock consolidated.
15 May 2024 — AGM, Q1 momentum and efficiency program
Parisot's first AGM saw the company report Q1 2024 sales growth of approximately 11% year-on-year and launch a €50m efficiency programme to lift profitability and margin delivery against 2024 targets [15]. The message shifted to "growth plus margin improvement"—investors saw tangible margin actions alongside top-line momentum. The stock broke out and rallied on the combination of organic growth and cost-efficiency measures.
19 Jul 2024 — Vizag Care (India) acquisition
Symrise acquired a 51% stake in Vizag Care Ingredients (Visakhapatnam), with closing reported 19 Jul 2024 [9]. The move expanded into India's ingredients market as a bolt-on to the Taste and Nutrition footprint, broadening emerging-market exposure. The stock consolidated with positive bias as investors priced in regional growth optionality.
17 Dec 2024 – 29 Jan 2025 — Probi public offer (initial tender)
Symrise launched a public cash offer for Probi AB on 17 Dec 2024. By 16 Jan 2025 the offer had been accepted for 2,840,101 shares (24.9%); the acceptance period extended to 29 Jan 2025 [9]. The move into probiotics and health ingredients appeared contiguous to Taste, Nutrition & Health but created short-term watchfulness among investors around financing and integration risk. The stock traded in a range as the market priced in possible takeover financing and integration considerations.
30 Jan 2025 — FY2024 results & investor presentation (margin validation)
Symrise reported FY2024 performance showing strong sales growth and material margin improvement. Organic growth reached approximately 8.7%; Group sales reached approximately €5.0bn; EBITDA €1,033m; EBITDA margin approximately 20.7% [7], [8], [11]. The company presented FY2024 investor slides at its analyst and investor conference. Delivery against the 20–23% mid-term EBITDA corridor materially validated the "profitable compounder" thesis. Investor focus moved to disciplined capital allocation and integration of acquired assets. The stock rallied on the beats, then consolidated over several months as the market reset expectations to higher steady-state margins.
1 Jan – 7 Feb 2025 — Sustainability & integration (CSO hire; Grasse campus)
Symrise appointed Dr. Isabella Tonaco as Chief Sustainability Officer effective 1 Jan 2025. Its SFA NEROLI subsidiary opened a new Fragrance campus in Grasse in Feb 2025, integrating the Romani and Néroli acquisitions [10], [59]. The moves strengthened governance and sustainability credentials and demonstrated integration of fine-fragrance assets into a scalable creative campus—positive for long-term customer positioning. The stock received structural support; gradual accumulation occurred on evidence of integration.
2025 — Governance updates and continued execution
Executive-board personnel continuity and contract extensions (including extension of Dr. Stephanie Coßmann's contract) were announced across 2025 filings and news [7], [1]. Continued M&A and integration activity proceeded. The market narrative matured to a large-cap compounder profile with diversified end markets (food, nutrition, pet, fragrance, care) while monitoring macro, FX and raw-material sensitivity. The stock traded in a range as investors balanced stronger fundamentals against macro and valuation normalisation.
11 Jul 2026 — Latest quoted share price
Latest reported share price: 88.6 (as of 2026-07-11). By mid-2026 the market appeared to price Symrise as a validated, M&A-driven compounder with improved margins and diversified end-market exposure. Investor sentiment balanced structural growth merits against macro, FX and commodity headwinds. The stock ranged around 88.6 after the 2024–2025 re-rating; the underlying multi-year uptrend remained preserved while shorter-term volatility reflected macro and M&A news flow.
Key risks and downside factors
Symrise operates in a concentrated global market for flavours, fragrances and specialty ingredients. Three dominant publicly listed players—Givaudan (GIVN.SIX, ISIN CH0010645932), IFF (IFF.NYSE, ISIN US4595061015) and dsm-firmenich (DSFIR.EURONEXT, ISIN CH1216478797)—set the competitive tone through pricing power, innovation velocity and client stickiness. Regional and specialty competitors like Takasago (4914.TYO, ISIN JP3454400007), Robertet (RBT.EURONEXT, ISIN FR0000039091) and Sensient (SXT.NYSE, ISIN US81725T1007) carve out defensible positions in their segments, but the structural advantages rest with scale. The operating environment carries real friction points. Commodity and supply-chain volatility can compress margins unexpectedly. Regulatory compliance costs drift upward across jurisdictions. Currency exposure—particularly to emerging markets where growth concentrates—introduces earnings noise. And the larger competitors have room to absorb margin pressure that smaller players cannot.
- Larger global competitors—Givaudan, IFF, dsm‑firmenich—and entrenched regional players create persistent pressure on pricing, margins, and market share.
- Raw-material and supply-chain risk stems from volatility or shortages in natural extracts, essential oils, and agricultural inputs—whether from climate disruption, crop failure, or logistics friction—which can elevate costs or limit production capacity.
- Regulatory and product-safety risk stems from evolving chemical, food, and cosmetics regulations across jurisdictions—REACH, labeling requirements, allergen rules—that drive up compliance costs and can constrain both formulations and market access.
- The company carries meaningful exposure to emerging markets, foreign exchange swings, trade and tariff shifts, and the execution demands of acquisitions—each capable of materially reshaping both reported results and margin performance.
Competitive landscape
Symrise operates in a consolidated global market for flavors, fragrances and nutrition ingredients where competitive advantage flows from scale, integrated research capabilities and access to natural and biotech inputs. The landscape includes three particularly relevant public competitors—Givaudan (CH0010645932), International Flavors & Fragrances (IFF, US4595061015) and Sensient (US81725T1007)—all larger incumbents alongside various regional specialists. This competitive density, combined with ongoing sector consolidation, exposes Symrise to meaningful margin compression and share loss. The company faces several material headwinds: raw-material and supply-chain instability, the complexity of navigating multi-jurisdictional regulatory and safety requirements, exposure to currency fluctuations and concentration in emerging markets and customer bases, and persistent pricing pressure from competitors [TradingView, Investing.com, Marketscreener, Craft.co].
| Company | Ticker |
|---|---|
| Givaudan SA | GIVN.SIX |
| International Flavors & Fragrances Inc. | IFF.NYSE |
| Sensient Technologies Corporation | SXT.NYSE |
Private competitors
- Firmenich
- Mane
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Symrise AG
Relative Performance vs Benchmarks
| Period | Symrise AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +6.70% | +3.16% | +4.11% |
| 3M | +23.06% | +17.75% | +11.66% |
| 6M | +27.16% | +28.49% | +17.98% |
| 1Y | +0.45% | -2.90% | -21.95% |
| 3Y | -3.92% | -60.36% | -79.62% |
| 5Y | -22.28% | -81.03% | -107.09% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 50.3 | 2.0 | 3.2 | 10.9 |
| 1Y ago | 20.3 | 2.0 | 3.4 | 14.2 |
| 3Y ago | 54.8 | 2.7 | 3.7 | 28.9 |
| 5Y ago | 33.2 | 3.1 | 6.7 | 20.9 |
Frequently Asked Questions
Where is the Symrise AG stock traded?
What does Symrise AG do?
What are the key metrics for SY1.XETRA?
How has Symrise AG's stock price performed?
How is SY1.XETRA valued?
Does SY1.XETRA pay dividends?
What are the key risks when investing in SY1.XETRA?
- Larger global competitors—Givaudan, IFF, dsm‑firmenich—and entrenched regional players create persistent pressure on pricing, margins, and market share.
- Raw-material and supply-chain risk stems from volatility or shortages in natural extracts, essential oils, and agricultural inputs—whether from climate disruption, crop failure, or logistics friction—which can elevate costs or limit production capacity.
- Regulatory and product-safety risk stems from evolving chemical, food, and cosmetics regulations across jurisdictions—REACH, labeling requirements, allergen rules—that drive up compliance costs and can constrain both formulations and market access.
- The company carries meaningful exposure to emerging markets, foreign exchange swings, trade and tariff shifts, and the execution demands of acquisitions—each capable of materially reshaping both reported results and margin performance.
Who are the main competitors of Symrise AG?
- Givaudan SA (GIVN.SIX)
- International Flavors & Fragrances Inc. (IFF.NYSE)
- Sensient Technologies Corporation (SXT.NYSE)
When does Symrise AG report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.25 EUR | 1.65% | 1.25% |
| 2025 | 1.20 EUR | 1.14% | |
| 2024 | 1.10 EUR | 1.08% | |
| 2023 | 1.05 EUR | 0.97% | |
| 2022 | 1.02 EUR | 0.93% | |
| 2021 | 0.97 EUR | 0.89% | |
| 2020 | 0.95 EUR | 0.98% | |
| 2020 | 0.95 EUR | 1.02% | |
| 2019 | 0.90 EUR | 1.04% | |
| 2018 | 0.88 EUR | 1.23% | |
| 2017 | 0.85 EUR | 1.34% | |
| 2016 | 0.80 EUR | 1.40% | |
| 2015 | 0.75 EUR | 1.32% | |
| 2014 | 0.70 EUR | 1.84% | |
| 2013 | 0.65 EUR | 1.99% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 4.93B | 5.00B | 4.73B | 4.62B | 3.83B |
| Operating income (EBIT) | 609.30M | 717.80M | 559.36M | 503.98M | 558.96M |
| Net income | 249.30M | 478.20M | 340.47M | 280.01M | 374.92M |
| Free cash flow | 521.05M | 667.49M | 449.31M | 109.94M | 347.40M |
| Total assets | 8.11B | 8.32B | 7.85B | 7.78B | 6.64B |
| Equity | 3.72B | 3.98B | 3.63B | 3.55B | 3.19B |
| Net debt | 1.60B | 1.84B | 2.17B | 2.23B | 1.35B |
PWP Leeway UG (haftungsbeschränkt)
